3.4.22.51	drug development	cruzipain is an attractive target for the development of novel trypanocidal drugs	
3.4.22.51	medicine	CatL-like sequences are excellent targets for diagnosis and genotyping of Trypanosoma rangeli by PCR	
3.4.22.51	medicine	cruzain is a primary cysteine protease expressed by the protozoan parasite Trypanosoma cruzi during Chagas disease infection, and thus, the development of inhibitors of this protein is a promising target for designing an effective therapy against the disease	
3.4.22.51	medicine	cruzipain inhibition is a chemotherapeutic approach for Chagas disease because of its trypanocidal activity and due to the inhibitory effect on TGF-beta activation	
3.4.22.51	molecular biology	in this study it is shown in murine macrophage cell line J774 as well as in murine bone marrow-derived macrophages, that cruzipain induces p38 phosphorylation with Trypanosoma cruzi infection triggering mainly JNK and ERK phosphorylation. Cruzipain also favors the survival in macrophages by changing the iNOS/arginase balance	
3.4.22.51	pharmacology	induction of RNAi against brucipain of Trypanosoma brucei does not cure mice from infection, however, 50% of these mice survive 60 days longer than uninduced controls. The ability of Trypanosoma brucei to cross an in vitro model of the human blood-brain barrier is also reduced by brucipain RNAi induction